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Hepatic copper accumulation isa regular feature ofprimary biliary cirrhosis(PBC). Thelevels aredirectly
related to the clinical stage of the disease. Since the copper values in PBC are comparable to Wilson's
disease, there is the potential for copper toxicity, although this is speculative since the two diseases differ in
the binding, distribution, and intracellular localization ofthe copper. The involvement ofcoppertoxicity in
the progression of PBC is supported by the observation that the highest values occurin association with the
hepatic failure that occurs in the advanced stage.
Corticosteroid therapy appears to decrease hepatic copper levels in PBC. Although this therapy does not
invariably lower the hepatic Cu content in patients with PBC, it does so in many individuals. Therapeutic
trials with d-penicillamine are in progress. When results are available they will guide us in the management
of individual patients with PBC. In the meantime, dietary copper should be restricted as is done in
management of Wilson's disease.
Since copper homeostasis is largely maintained by biliary excretion, any process
which results in chronic cholestasis may be associated with hepatic copper accumula-
tion [1,2]. Increased hepatic copper levels have been observed in primary biliary
cirrhosis (PBC) [2-5] and prolonged bile duct obstruction [5], with thelevels inPBC
frequently being in the range associated with untreated Wilson's disease [6,7]. The
hepatic damage in Wilson's disease is attributed to excess copper although the
pathogenesis of the tissue injury has not been defined [8]. Since the pathogenesis of
hepatic damage in PBC remains unknown, it is possible that copper toxicity
contributes to the progression of the liver disease. This suggestion is supported by
comparable hepatic copper concentrations in both diseases and has resulted in the
initiation of therapeutic trials with d-penicillamine in PBC [9-11].
This study was initiated to determine theregularity ofcopper accumulation inPBC
and document the relationship between the copper levels and the clinical stage ofthe
disease.
METHODS
The diagnosis of PBC was established in 56 patients by the usual criteria of a
compatible clinical picture, presence of antimitochondrial antibody, and appropriate
morphological changes [12,13]. The patients were classified as asymptomatic (17),
active (32), or advanced (7), according to their clinical status. The patients in the
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asymptomatic group were recognized because of abnormalities in the liver studies,
particularly the alkaline phosphatase, evidence of a lipid disorder or hepatomegaly.
All patients in this group had a serum bilirubin ofless than 1.2 mg/dl. Patients in the
active group had symptoms referable to chronic liver disease. These patients were
generally referred for evaluation because of active liver disease, jaundice, or pruritis.
In this group of 32 patients, there were 12 who had been treated for periods longer
than 3 months with corticosteroids in varying dosages. The patients in the advanced
group werejaundiced with severe cholestasis and evidence ofprogressive liverfailure.
Five of the seven patients in this category died during the period of observation.
Liver biopsy specimens were handled to prevent trace metal contamination. The
tissue was freeze-dried and the dryweight determined. The dried tissue was wet-ashed
with nitric-sulfuric acid, diluted and analyzed for copper by atomic absorption
spectrophotometry utilizing peak-retrieval circuitry [14]. Hepatic copper values are
expressed as,sg/g liver (dry weight). Based on the literature and analysis in patients
with a variety of diseases, 50 jsg/g or less was considered to be normal [5,8].
RESULTS
Figure 1 shows the individual hepatic copper values for each of the 56 patients in
relationship to the clinical stage. In the asymptomatic group, hepatic copper was
114 ± 81 jg/g (mean ± S.D.) with a range of 32-298jg/g. Thirteen of the 17 values
were abnormal, although only one exceeded 250 pg/g, the level which might be
confused with Wilson's disease [6,7]. In the active stage, the hepatic copper level was
324 ± 292,ug/g (mean ± S.D.) with a range of 13-1,249 ;,g/g. Twenty-seven of 32
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FIG. 1. Hepatic copper levels, ,ug/g (dry weight), in asymptomatic, active and advanced stages ofprimary biliary
cirrhosis. Shaded area, normal range; horizontal lines, mean values.
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values were abnormal and 16 of 32 exceeded 250 Ag/ g. All values were markedly
abnormal in the advanced stage, 1,090 i 449 pg/g (mean ± S.D.) with a range of
676-1,925 Ag/g. Because of the distribution, log transformations were performed on
all data. There was a highly significant difference between groups when evaluated by
a one-way analysis of variance. Newman-Keuls tests for all possible pair-wise
comparisons showed that the groups are significantly (p = .01) different from each
other.
When patients in the active stage were evaluated for corticosteroid therapy, 12
were found to have received varying dosages for periods greater than three months.
Figure 2 compares the results in the steroid group with the non-steroid group. The
hepatic copper level on the steroid group was 240 ± 251 ; g/g (mean ± S.D.) with a
range of 13-790 JAg/g. Four values were in the normal range and two were near
normal (69 ug/g). In the non-steroid group the level was 403 ± 304 ILg/g (mean ±
S.D.) and a range of 32-1,249 pg/g. The one normal value of 32,g/g occurred in a
patient with mild symptoms and might well have been included in the asymptomatic
group. Analysis by Student t-test showed a significant (p = .02) difference between
the mean hepatic copper levels in the two groups. When the number of values in the
normal range in the steroid and non-steroid groups are compared (using Fisher's
exact probability test) significantly more are in the steroid group (p = .05). In the
steroid group, 4 of 12 values were normal while only 1 of 20 was normal in the non-
steroid group. The analysis was biased against a difference being related to corticoste-
roid therapy since values of 342 and 790 pg/1g were included in the steroid group
although this therapy had been terminated one and two years before evaluation.
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FIG. 2. Hepatic copper levels, ug/g (dry weight), during active stage of primary biliary cirrhosis. Left column, 12
patients who received corticosteroids before evaluation; right column, 20 patients who did not receive corticosteroids.
Shaded area, normal range; horizontal lines, mean values.GORDON D. BENSON
During the study nine patients had repeat biopsies after receiving continuous or
intermittent corticosteroid therapy for intervals of 12-46 months. Six of the nine
showed a decrease in hepatic copper. One patient showed an increase from 60 to 492
,g/g and progression from asymptomatic to an active stage over four years. This
patient was found to be using a multivitamin preparation which contained 2 mg of
copper sulfate on a regular basis during the four-year period. This may have
contributed to the increase in hepatic copper, and, possibly, to the progression ofthe
disease process. Five of six patients who did not receive steroids showed a mild
increase in hepatic copper during11 to 49 months of observation. Because these
observations were not controlled they were not analyzed further.
DISCUSSION
The current study shows that there is a clear relationship between the levels of
hepatic copper and the stage of the disease. Hepatic copper accumulation is a regular
feature ofPBC at the active or advanced stage. Thehepatic copper levels are directly
related to the severity of cholestasis although they may also be a reflection of the
duration of the disease process.
An unanswered question is whether copper accumulation is involved in the
pathogenesis of PBC, or whether it is merely a result of prolonged cholestasis.
Although it is attractive to speculate that copper toxicity is responsible for tissue
damage in Wilson's disease and PBC, there are some significant differences in the
localization and binding of the copper which limit the attractiveness of this reason-
ing. The excess copper in Wilson's disease appears to be associated mainly with the
particulate fraction of the subcellular compartments, predominately the lysosomes
[6,15], whereas the excess copper is in the supernatant fraction in PBC [16]. In
addition, the copper-binding protein demonstrated in the periportal hepatocytes of
patients with prolonged cholestasis [17], particularly the form observed in PBC [18]
appears to differ from that observed in Wilson's disease. Therefore, although the
excess copper in the hepatocytes may contribute to progressiveliver damage, the
mechanism of injury may differ from that in Wilson's disease since the site of
deposition, distribution, and binding are different.
Since the mean hepatic copper level was only1 14ug/ g at the asymptomatic stage,
marked copper accumulation is not associated with the initial inflammatory process.
This contrasts with Wilson's disease where the highest hepatic copper levels occur
during the asymptomatic or preclinical period [6,7,8]. The extremely elevated levels
noted during the advanced stage ofPBC, mean value of 1,090 ug/g, were associated
with hepatic failure. Six of the seven patients in this group died as a result of the
disease. This relationship between the hepatic copper levels and the stages of the
disease supports the involvement ofcopper toxicity in the progression of PBC rather
than the initiation of the disease, as appears to be the case in Wilson's disease.
Between the asymptomatic and the advanced stages were patients judged to be in
an active phase of the disease. In this group, the values ranged from normal to 1,249
Ag/g with a mean of 342,g/g. Initially, all patients studied in this phase of the
disease had elevated hepatic copper levels but, as the series was extended, several
were observed to be normal or near normal. Therefore, it appears that PBC can be
symptomatic without significant elevation of hepatic copper. Analysis of these
patients disclosed that 4 of 5 with normal levels had been treated previously with
corticosteroids. Corticosteroid therapy- has been widely used for chronic active
hepatitis and, because of confusion with regard to the diagnosis, is occasionally
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prescribed for the patient with PBC. Corticosteroid therapy has been considered to
be contraindicated in PBC because of potentiation of bone disease [12] and, in one
published series, the absence of a response was used to differentiate PBC from
chronic active hepatitis [19]. Nevertheless, some patients with established PBC do
appear to show clinical improvement with this therapy, although the benefit may not
be great enough to justify long-term treatment. In the current study those patients
who were normal or near normal during the active stage of the disease were very
likely to have been treated with corticosteroids. Six of nine patients who received
steroid therapy during this study showed a mild decrease in hepatic copper. These
observations suggest that corticosteroid therapy facilitates the biliary excretion of
copper perhaps by decreasing the inflammatory process, though the mechanism has
not been demonstrated. This response may occur in the absence ofsignificant clinical
improvement and suggests that corticosteroids have an effect in PBC that has not
been recognized previously.
Controlled studies are in progress to evaluate therapy with d-penicillamine in PBC
because of the abnormal hepatic copper levels [9,11]. Because of the chronicity of
PBC it may not be possible to determine the beneficial effect of this therapy for
several years. Any beneficial effect may be difficult to document unless the patients
are observed for prolonged periods since it is possible that treatment prevents or
delays the onset of hepatic failure, rather than reversing the process present at the
time of initiation of therapy. If copper removal were the only beneficial effect of d-
penicillamine in PBC, one would not expect much change in patients in the
asymptomatic phase of the disease. It should be remembered that d-penicillamine
also has the potential for altering immune responses [20] and retarding fibrogenesis
[21,22], factors which appear to be operative in the pathogenesis of PBC. Since
therapy with d-penicillamine is frequently associated with side-effects, it seems
prudent to await results of the controlled studies before initiating treatment in
individual patients. Until such information is available, it may be appropriate to
restrict copper intake as is done for therapy of Wilson's disease.
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